User fees are "vital" to future of generics, FDA's Hamburg says

02/20/2011 | NYTimes.com

FDA Commissioner Margaret Hamburg has endorsed a proposal that would impose fees to accelerate the regulatory process for generic drugs and reduce a backlog of applications. At the Generic Pharmaceutical Association's annual meeting, Hamburg said "this is really a critical time, and the user fee program is clearly, clearly important, vital, to the future of the generic drug industry."

View Full Article in:

NYTimes.com

Published in Brief:

SmartBrief Job Listings for Health Care